annb0t
Top 20
Immutep Limited
Media Release
Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacy Triple combination therapy has achieved a 67% response rate and 91% disease control rate in metastatic 1st line non-small cell lung cancer patients (N=21) despite 81% of patients having low or negative PD-L1 expression
SYDNEY, AUSTRALIA, May 24, 2023 (GLOBE NEWSWIRE) -- Immutep L...
>>> Read more: Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
Media Release
Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacy Triple combination therapy has achieved a 67% response rate and 91% disease control rate in metastatic 1st line non-small cell lung cancer patients (N=21) despite 81% of patients having low or negative PD-L1 expression
SYDNEY, AUSTRALIA, May 24, 2023 (GLOBE NEWSWIRE) -- Immutep L...
>>> Read more: Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
